Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study).

ABSTRACT:

Introduction

While ixekizumab (IXE) has demonstrated efficacy in axial spondyloarthritis (axSpA) clinical trials, real-world evidence is limited. This study describes the characteristics and treatment persistence of axSpA patients receiving IXE in routine clinical practice in Spain.

Methods

A retrospective study of axSpA patients treated with IXE was carried out in ten hospitals. Demographic, clinical, treatment-related characteristics, persistence and disease activity were collected at baseline, 12, 24 and 52 weeks. Descriptive analysis and Kaplan-Meier methods were used.

Results

The study included 106 axSpA patients, 69.8% had r-axSpA, 58.5% were male, and 63% had overweight or obesity. Mean (SD) disease duration was 12.8 (12.3) years. 98.1% had received b/tsDMARDs

SUBMITTER: Campos C 

PROVIDER: S-EPMC12827647 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature